Teva Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Teva (TEVA)
Idag, 20:55
Idag, 20:55
Teva Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Teva (TEVA)
PR Newswire
NEW YORK, Nov. 20, 2026
Selling at a loss does not end your rights. TEVA investors hurt by the roughly 8.74% decline that followed the immediate exit of Teva's Global R&D chief may be eligible to seek recovery.
NEW YORK , Nov. 20, 2026 /PRNewswire/ -- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares fell roughly 8.74% as news broke that Eric Hughes, its Executive Vice President of Global R&D and Chief Medical Officer, was leaving effective immediately. If you bought TEVA and lost money on that decline, you have rights, whether you still hold the stock or have already sold it. Affected shareholders are encouraged to submit your TEVA loss details for review now. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.

Hughes oversaw both Teva's Global R&D organization and its medical function. He left days after Teva highlighted its innovative-medicines pipeline and long-term growth plans. David Gardiner is now serving as interim R&D lead while the Company searches for a permanent successor.
The investigation concerns potential securities law violations. It is examining whether Hughes' departure or Teva's prior R&D statements called for additional disclosure to shareholders. Eligibility depends on when you purchased, not on whether you held through the drop. There is no cost to have your losses evaluated, and no minimum loss is required to come forward.
If the TEVA decline cost you money, find out whether you can recover your losses or call (888) SueWallSt.
WHY SUEWALLST : SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured billions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the TEVA Investigation
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Teva made materially false or misleading statements about its R&D leadership and the innovative-medicines pipeline it highlighted days before Eric Hughes' departure. Teva then disclosed that Hughes, its Executive Vice President of Global R&D and Chief Medical Officer, was leaving effective immediately, and the stock price fell roughly 8.74%.
Q: When did Teva allegedly mislead investors? A: The investigation concerns statements made before Teva announced Eric Hughes' immediate departure. Those statements allegedly caused investors to purchase TEVA securities at inflated prices.
Q: How much did TEVA stock drop? A: Shares fell approximately 8.74% after the Company disclosed the immediate departure of Eric Hughes, its Executive Vice President of Global R&D and Chief Medical Officer. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: What do TEVA investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my TEVA shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought TEVA and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia: https://www.prnewswire.com/news-releases/teva-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-teva-teva-302947211.html
SOURCE SueWallSt.com
Idag, 20:55
Teva Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Teva (TEVA)
PR Newswire
NEW YORK, Nov. 20, 2026
Selling at a loss does not end your rights. TEVA investors hurt by the roughly 8.74% decline that followed the immediate exit of Teva's Global R&D chief may be eligible to seek recovery.
NEW YORK , Nov. 20, 2026 /PRNewswire/ -- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares fell roughly 8.74% as news broke that Eric Hughes, its Executive Vice President of Global R&D and Chief Medical Officer, was leaving effective immediately. If you bought TEVA and lost money on that decline, you have rights, whether you still hold the stock or have already sold it. Affected shareholders are encouraged to submit your TEVA loss details for review now. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com or by telephone at (888) SueWallSt.

Hughes oversaw both Teva's Global R&D organization and its medical function. He left days after Teva highlighted its innovative-medicines pipeline and long-term growth plans. David Gardiner is now serving as interim R&D lead while the Company searches for a permanent successor.
The investigation concerns potential securities law violations. It is examining whether Hughes' departure or Teva's prior R&D statements called for additional disclosure to shareholders. Eligibility depends on when you purchased, not on whether you held through the drop. There is no cost to have your losses evaluated, and no minimum loss is required to come forward.
If the TEVA decline cost you money, find out whether you can recover your losses or call (888) SueWallSt.
WHY SUEWALLST : SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured billions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the TEVA Investigation
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Teva made materially false or misleading statements about its R&D leadership and the innovative-medicines pipeline it highlighted days before Eric Hughes' departure. Teva then disclosed that Hughes, its Executive Vice President of Global R&D and Chief Medical Officer, was leaving effective immediately, and the stock price fell roughly 8.74%.
Q: When did Teva allegedly mislead investors? A: The investigation concerns statements made before Teva announced Eric Hughes' immediate departure. Those statements allegedly caused investors to purchase TEVA securities at inflated prices.
Q: How much did TEVA stock drop? A: Shares fell approximately 8.74% after the Company disclosed the immediate departure of Eric Hughes, its Executive Vice President of Global R&D and Chief Medical Officer. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.
Q: What do TEVA investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my TEVA shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought TEVA and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia: https://www.prnewswire.com/news-releases/teva-investigation-notice-suewallst-notifies-investors-of-pending-investigation-into-teva-teva-302947211.html
SOURCE SueWallSt.com
Börsen
Analyser
Anthropics IPO
Börsen
Analyser
Anthropics IPO
1 DAG %
Senast
OMX Stockholm 30
−2,51%
(vid stängning)
Anthropic
Idag, 14:39
Anthropics rekordnotering växer
USA-börserna
Idag, 14:37
Anthropic rasar i förhandeln
OMX Stockholm 30
1 DAG %
Senast
3 175,06